178 related articles for article (PubMed ID: 21239043)
1. Significance of dysadherin and E-cadherin expression in differentiated-type gastric carcinoma with submucosal invasion.
Maehata Y; Hirahashi M; Aishima S; Kishimoto J; Hirohashi S; Yao T; Takashima H; Tsuneyoshi M; Oda Y
Hum Pathol; 2011 Apr; 42(4):558-67. PubMed ID: 21239043
[TBL] [Abstract][Full Text] [Related]
2. Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression.
Izumi T; Oda Y; Hasegawa T; Nakanishi Y; Kawai A; Sonobe H; Takahira T; Kobayashi C; Yamamoto H; Tamiya S; Hirohashi S; Iwamoto Y; Tsuneyoshi M
Am J Surg Pathol; 2007 Jan; 31(1):85-94. PubMed ID: 17197923
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of dysadherin expression in patients with non-small cell lung cancer.
Tamura M; Ohta Y; Tsunezuka Y; Matsumoto I; Kawakami K; Oda M; Watanabe G
J Thorac Cardiovasc Surg; 2005 Sep; 130(3):740-5. PubMed ID: 16153922
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
[TBL] [Abstract][Full Text] [Related]
5. Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC.
Ono K; Uramoto H; Hanagiri T
Anticancer Res; 2010 Sep; 30(9):3273-8. PubMed ID: 20944097
[TBL] [Abstract][Full Text] [Related]
6. Mixed-histologic-type submucosal invasive gastric cancer as a risk factor for lymph node metastasis: feasibility of endoscopic submucosal dissection.
Hanaoka N; Tanabe S; Mikami T; Okayasu I; Saigenji K
Endoscopy; 2009 May; 41(5):427-32. PubMed ID: 19418397
[TBL] [Abstract][Full Text] [Related]
7. Abnormal expression of E-cadherin and beta-catenin may be a molecular marker of submucosal invasion and lymph node metastasis in early gastric cancer.
Tanaka M; Kitajima Y; Edakuni G; Sato S; Miyazaki K
Br J Surg; 2002 Feb; 89(2):236-44. PubMed ID: 11856141
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma.
Shimada Y; Hashimoto Y; Kan T; Kawamura J; Okumura T; Soma T; Kondo K; Teratani N; Watanabe G; Ino Y; Sakamoto M; Hirohashi S; Imamura M
Oncology; 2004; 67(1):73-80. PubMed ID: 15459499
[TBL] [Abstract][Full Text] [Related]
9. E-cadherin expression as a differentiation marker in gastric cancer.
Karayiannakis AJ; Syrigos KN; Chatzigianni E; Papanikolaou S; Karatzas G
Hepatogastroenterology; 1998; 45(24):2437-42. PubMed ID: 9951940
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of dysadherin and E-cadherin expression in patients with head and neck cancer treated by radiation therapy.
Muramatsu H; Akimoto T; Maebayashi K; Kita M; Mitsuhashi N
Anticancer Res; 2008; 28(6B):3859-64. PubMed ID: 19192641
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of dysadherin expression in gastric cancer patients.
Shimada Y; Yamasaki S; Hashimoto Y; Ito T; Kawamura J; Soma T; Ino Y; Nakanishi Y; Sakamoto M; Hirohashi S; Imamura M
Clin Cancer Res; 2004 Apr; 10(8):2818-23. PubMed ID: 15102690
[TBL] [Abstract][Full Text] [Related]
12. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
Joo M; Lee HK; Kang YK
Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
[TBL] [Abstract][Full Text] [Related]
13. Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers.
Boo YJ; Park SS; Kim JH; Mok YJ; Kim SJ; Kim CS
J Surg Oncol; 2007 Feb; 95(2):110-7. PubMed ID: 17066436
[TBL] [Abstract][Full Text] [Related]
14. E-cadherin expression in early gastric carcinoma and correlation with lymph node metastasis.
Yi Kim D; Kyoon Joo J; Kyu Park Y; Yeob Ryu S; Soo Kim H; Kyun Noh B; Hwa Lee K; Hyuk Lee J
J Surg Oncol; 2007 Oct; 96(5):429-35. PubMed ID: 17786966
[TBL] [Abstract][Full Text] [Related]
15. An immunohistochemical study of E-cadherin expression with correlations to clinicopathological features in gastric cancer.
Shun CT; Wu MS; Lin JT; Wang HP; Houng RL; Lee WJ; Wang TH; Chuang SM
Hepatogastroenterology; 1998; 45(22):944-9. PubMed ID: 9755986
[TBL] [Abstract][Full Text] [Related]
16. Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype.
Watari J; Saitoh Y; Fujiya M; Shibata N; Tanabe H; Inaba Y; Okamoto K; Maemoto A; Ohta T; Yasuda A; Ayabe T; Ashida T; Yokota K; Obara T; Kohgo Y
J Gastroenterol; 2004; 39(2):104-12. PubMed ID: 15069616
[TBL] [Abstract][Full Text] [Related]
17. Loss of phenotypic expression is related to tumour progression in early gastric differentiated adenocarcinoma.
Nakamura T; Yao T; Kabashima A; Nishiyama K; Maehara Y; Tsuneyoshi M
Histopathology; 2005 Oct; 47(4):357-67. PubMed ID: 16178890
[TBL] [Abstract][Full Text] [Related]
18. Re-expression of the cadherin-catenin complex in lymph nodes with metastasis in advanced gastric cancer: the relationship with patient survival.
Liu J; Ikeguchi M; Nakamura S; Kaibara N
J Exp Clin Cancer Res; 2002 Mar; 21(1):65-71. PubMed ID: 12071532
[TBL] [Abstract][Full Text] [Related]
19. Dysadherin: expression and clinical significance in thyroid carcinoma.
Sato H; Ino Y; Miura A; Abe Y; Sakai H; Ito K; Hirohashi S
J Clin Endocrinol Metab; 2003 Sep; 88(9):4407-12. PubMed ID: 12970317
[TBL] [Abstract][Full Text] [Related]
20. [Relationship between abnormal expression of beta-catenin in gastric carcinoma and survival].
Zhou YN; Li M
Ai Zheng; 2002 May; 21(5):536-40. PubMed ID: 12452049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
